New narcolepsy drug tested in tiny trial – but study halted early

NCT ID NCT06961266

Terminated Symptom relief Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called JZP441 in just 6 adults with narcolepsy type 1, a condition that causes sudden daytime sleepiness. The goal was to see if the drug could help people stay awake longer, as measured by a standard sleep test. However, the study was terminated early, so we have limited information on how well it worked or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JZP441 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment to help people with narcolepsy stay awake during the day.
What could go wrong: This is a very early, tiny trial (only 6 people) that was terminated, so results are limited. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY

Contacts and locations

Locations

Clinical Trial Site

Atlanta, Georgia, 30328, United States
Clinical Trial Site

Cincinnati, Ohio, 45245, United States
Clinical Trial Site

Columbia, South Carolina, 29201, United States
Clinical Trial Site

Austin, Texas, 78731, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.